JP2005041832A - Gargle containing local anesthetic - Google Patents
Gargle containing local anesthetic Download PDFInfo
- Publication number
- JP2005041832A JP2005041832A JP2003278888A JP2003278888A JP2005041832A JP 2005041832 A JP2005041832 A JP 2005041832A JP 2003278888 A JP2003278888 A JP 2003278888A JP 2003278888 A JP2003278888 A JP 2003278888A JP 2005041832 A JP2005041832 A JP 2005041832A
- Authority
- JP
- Japan
- Prior art keywords
- local anesthetic
- gargle
- drug
- anesthetic drug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、局所麻酔薬物含有含嗽剤に関する。詳しくは口内炎などの口中の痛み緩和に著しく効果の高い局所麻酔薬物含有含嗽剤に関する。 The present invention relates to a local anesthetic drug-containing gargle. Specifically, the present invention relates to a local anesthetic drug-containing gargle which is remarkably effective in reducing pain in the mouth such as stomatitis.
癌患者においては、抗癌剤の開発、放射線療法により治療あるいは延命が期待されるようになりつつあるが、一方で抗癌剤などの治療による副作用により精神的・肉体的苦痛を感じていることが多い。このような癌治療の副作用としては、難治性の重篤な口内炎が知られている。化学療法初期から口内乾燥、味覚異常、疼痛などが出現し、栄養状態の悪化、化学療法の中断等の問題が発生している。そのような口内炎の痛み対策として、局所麻酔薬物は非常に有効である。 Cancer patients are expected to be treated or prolong their lives by developing anti-cancer drugs and radiation therapy, but on the other hand, they often feel mental and physical distress due to side effects of such treatments as anti-cancer drugs. As a side effect of such cancer treatment, refractory severe stomatitis is known. From the beginning of chemotherapy, dry mouth, abnormal taste, pain, etc. have appeared, causing problems such as deterioration of nutritional status and interruption of chemotherapy. Local anesthetic drugs are very effective as countermeasures against such stomatitis pain.
実際、近年、院内処方で局所麻酔薬物であるリドカインをカラギーナンによりゼリー化した製剤が癌患者の口内炎の痛み緩和に用いられていることが知られている。 In fact, in recent years, it is known that a preparation obtained by jelly-forming lidocaine, which is a local anesthetic drug, in a hospital prescription with carrageenan is used for pain relief of stomatitis in cancer patients.
これらの局所麻酔薬含有の口内炎の痛み緩和の製剤としては貼付剤、軟膏剤、含嗽剤等があげられるが、癌治療の副作用による口内炎は患部が広く、含嗽剤が適していると考えられる。 These local anesthetic-containing preparations for pain relief of stomatitis include patches, ointments, gargles and the like, but it is thought that mouthwashes due to side effects of cancer treatment have a wide affected area and gargles are suitable.
しかしながら、局所麻酔薬を含嗽剤とするとき、リドカインに代表される局所麻酔薬物は重篤な副作用としてショック症状、けいれん等の中毒症状が知られており、また最近リドカインのアレルギー問題などが指摘されるなど、必要量以上の薬剤の摂取がない製剤が求められている。具体的には、より少ない薬物濃度で十分な効果を得ることのできる製剤や薬剤含嗽後に水で含嗽し薬物を取り除いたとしても、十分な効果の得られる製剤などが求められている。すなわち、局所麻酔薬の口内粘膜に対する吸収効率が良く、また吸収速度の高い局所麻酔薬物含有含嗽剤が求められている。 However, when local anesthetics are used as gargles, local anesthetics such as lidocaine are known to have serious side effects such as shock symptoms and convulsions, and recently allergic problems of lidocaine have been pointed out. For example, there is a need for a formulation that does not consume more than the required amount of drug. Specifically, there is a demand for a preparation capable of obtaining a sufficient effect with a smaller drug concentration, a preparation capable of obtaining a sufficient effect even if the drug is removed by rinsing with water after the drug is impregnated. That is, a local anesthetic drug-containing gargle having a high absorption efficiency of the local anesthetic into the oral mucosa and a high absorption rate is desired.
上記のような状況から、本発明の解決課題は、局所麻酔剤を含嗽剤として用いる場合に求められている、局所麻酔薬の口内粘膜に対する吸収効率が良く、また吸収速度の高い局所麻酔薬物含有含嗽剤の提供にある。 From the situation as described above, the problem to be solved by the present invention is that when a local anesthetic is used as a gargle, the local anesthetic has a good absorption efficiency for the oral mucosa and has a high absorption rate. To provide gargle.
本発明者らは鋭意検討を行った結果、局所麻酔薬物含有含嗽剤の製剤のpH調整により局所麻酔薬物の効力が改善されることを見出した。このようにして本発明を完成した。
本発明は、以下を包括する。
As a result of intensive studies, the present inventors have found that the efficacy of the local anesthetic drug is improved by adjusting the pH of the preparation of the gargle containing the local anesthetic drug. Thus, the present invention was completed.
The present invention encompasses the following.
製剤pHが8.0未満であることを特徴とする局所麻酔薬物含有含嗽剤。 A local anesthetic drug-containing gargle characterized by having a formulation pH of less than 8.0.
[2]局所麻酔薬物はリドカインまたはその薬学上許容される塩である[1]に記載の局所麻酔薬物含有含嗽剤。 [2] The local anesthetic drug-containing gargle according to [1], wherein the local anesthetic drug is lidocaine or a pharmaceutically acceptable salt thereof.
[3]製剤pHが6.0以上8.0未満であることを特徴とする[1]〜[2]記載の局所麻酔薬物含有含嗽剤。 [3] The local anesthetic drug-containing gargle according to [1] to [2], wherein the formulation pH is 6.0 or more and less than 8.0.
[4]製剤pHが6.5以上7.5未満であることを特徴とする[1]〜[3]記載の局所麻酔薬物含有含嗽剤。 [4] The local anesthetic drug-containing gargle according to [1] to [3], wherein the preparation pH is 6.5 or more and less than 7.5.
局所麻酔薬の口内粘膜に対する吸収効率が良く、また吸収速度の高い局所麻酔薬物含有含嗽剤の提供にある。 An object of the present invention is to provide a local anesthetic drug-containing gargle having a high absorption efficiency of the local anesthetic to the oral mucosa and a high absorption rate.
本発明の局所麻酔薬物含有含嗽剤の製剤のpHとしては、8.0未満が挙げられ、好ましくは6.0〜8.0が挙げられ、特に好ましくは6.5〜7.5が挙げられる。pH8.0以上の条件では局所麻酔薬物の析出がみられ、局所麻酔薬の効力も低く、また薬物による浮遊物のため含嗽剤として成立しない。pHが6.5未満であると局所麻酔薬の効力が若干弱くなり、pH6未満であるとよりいっそう効力低下がおこる。 The pH of the preparation of the local anesthetic drug-containing gargle of the present invention includes less than 8.0, preferably 6.0 to 8.0, and particularly preferably 6.5 to 7.5. . Precipitation of a local anesthetic drug is observed at pH 8.0 or higher, and the efficacy of the local anesthetic is low, and it is not established as a gargle because of a suspended substance due to the drug. When the pH is less than 6.5, the efficacy of the local anesthetic is slightly weakened, and when the pH is less than 6, the efficacy is further reduced.
本発明の局所麻酔薬物含有含嗽剤に使用される局所麻酔薬物としては、例えばリドカイン、パラアミノ安息香酸エチル、オキシブプロカイン、テトラカイン、プロカイン、パラブチルアミノ安息香酸ジエチルアミノエチルまたはこれらの薬学上許容される塩が挙げられ、これらの混合物であってもよい。特に好ましくは、塩酸リドカインが挙げられる。なぜなら本実施例にて効果が実証されているからである。 Examples of the local anesthetic drug used in the local anesthetic drug-containing gargle of the present invention include lidocaine, ethyl paraaminobenzoate, oxybuprocaine, tetracaine, procaine, diethylaminoethyl parabutylaminobenzoate, or a pharmaceutically acceptable salt thereof. Or a mixture thereof. Particularly preferred is lidocaine hydrochloride. This is because the effect is demonstrated in this embodiment.
本発明の局所麻酔薬物含有含嗽剤はpH調整剤を使用することができる。そのpH調整剤としては、例えば塩酸、希塩酸、ホウ酸、硫酸、リン酸等の酸およびその塩、クエン酸、コハク酸、リンゴ酸、酒石酸、乳酸、アスコルビン酸、フマル酸、マレイン酸、グルコン酸、グルクロン酸、酢酸等の有機酸およびその塩、水酸化カリウム、水酸化カルシウム、水酸化ナトリウム、水酸化マグネシウム、炭酸ナトリウム、炭酸水素ナトリウム等の塩基が挙げられ、これらの混合物であっても良い。特に好ましくはクエン酸、リンゴ酸の有機酸および水酸化ナトリウム、炭酸水素ナトリウムの混合物が挙げられる。 A pH adjuster can be used in the local anesthetic drug-containing gargle of the present invention. Examples of the pH adjuster include acids such as hydrochloric acid, dilute hydrochloric acid, boric acid, sulfuric acid, phosphoric acid and salts thereof, citric acid, succinic acid, malic acid, tartaric acid, lactic acid, ascorbic acid, fumaric acid, maleic acid, gluconic acid. , Organic acids such as glucuronic acid, acetic acid and salts thereof, and bases such as potassium hydroxide, calcium hydroxide, sodium hydroxide, magnesium hydroxide, sodium carbonate, sodium hydrogen carbonate, and a mixture thereof. . Particularly preferred is a mixture of citric acid, an organic acid of malic acid, and sodium hydroxide and sodium bicarbonate.
本発明の局所麻酔薬物含有含嗽剤は例えばアスパルテーム、サッカリン、サッカリンナトリウム、ステビア、ソーマチン、エリスリトール、ソルビトール、キシリトール等の甘味料を配合することができ、その場合は、より好ましい服用感が得られる。 The local anesthetic drug-containing gargle of the present invention can contain sweeteners such as aspartame, saccharin, saccharin sodium, stevia, thaumatin, erythritol, sorbitol, xylitol, and in this case, a more preferable feeling of administration can be obtained.
本発明の局所麻酔薬物含有含嗽剤はレモン、オレンジ、グレープフルーツ、パイン、バナナ、チョコレート、ヨーグルト、バニラ、メントール等の香料を配合することができ、その場合は、より好ましい服用感が得られる。 The local anesthetic drug-containing gargle of the present invention can be blended with a fragrance such as lemon, orange, grapefruit, pine, banana, chocolate, yogurt, vanilla, menthol, etc. In this case, a more preferable feeling of administration can be obtained.
本発明の局所麻酔薬物含有含嗽剤においては、薬学上許容される無毒性かつ不活性な添加物を添加することもできる。これらの添加物としては、アルギン酸ナトリウム、カルボキシビニルポリマー、カルメロースナトリウム、キサンタンガム、プロピレングリコール、グリセリン、濃グリセリン、ヒドロキシエチルセルロース、ヒドロキシエチルメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、ポリアクリル酸、ポリアクリル酸ナトリウム、ポリビニルアルコール等の粘稠剤、その他緩衝剤、着色剤、矯味剤、吸着剤、安定化剤、懸濁剤、抗酸化剤、防腐剤等が挙げられる。 In the local anesthetic drug-containing gargle of the present invention, a pharmaceutically acceptable non-toxic and inert additive can also be added. These additives include sodium alginate, carboxyvinyl polymer, carmellose sodium, xanthan gum, propylene glycol, glycerin, concentrated glycerin, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyacrylic acid, Examples include thickeners such as sodium polyacrylate and polyvinyl alcohol, other buffers, colorants, flavoring agents, adsorbents, stabilizers, suspending agents, antioxidants, and preservatives.
以下に、実施例および実験例を挙げてさらに具体的に説明するが、本発明は必ずしもこれらに限定されるものではない。なお、本実施例および比較例における配合量の値はすべて質量%である。 Hereinafter, the present invention will be described more specifically with reference to examples and experimental examples, but the present invention is not necessarily limited thereto. In addition, the value of the compounding quantity in a present Example and a comparative example is all the mass%.
(実施例1)局所麻酔薬物含有含嗽剤の調製
本発明の局所麻酔薬物含有含嗽剤を、以下の配合量で調製した。
配合量および製剤pHを表1に示す。
(Example 1) Preparation of a local anesthetic drug-containing gargle The local anesthetic drug-containing gargle of the present invention was prepared in the following amounts.
The blending amount and formulation pH are shown in Table 1.
(実験例1)官能試験
実施例1に示した製剤を用いて官能試験を実施した。
(Experimental example 1) Sensory test The sensory test was implemented using the formulation shown in Example 1.
被験者10人にそれぞれの製剤10mLを用いて、30秒間含嗽させ、続いて30mLの水で3回含嗽させた。5分後の局所麻酔薬物の効果を次の指標で判定させた。
「全く感じない」
「やや感じる」
「感じる」
「強く感じる」
以上
Ten subjects were grated for 30 seconds with 10 mL of each formulation, followed by 3 times of maturation with 30 mL of water. The effect of the local anesthetic drug after 5 minutes was determined by the following index.
"I don't feel at all"
"I feel a little"
"feel"
"I feel strongly"
more than
同一被験者でそれぞれの官能試験は少なくとも2時間以上休薬して行った。
それぞれの指標に該当する被験者数を表2に示す。
Each sensory test was performed on at least 2 hours withdrawn from the same subject.
Table 2 shows the number of subjects corresponding to each index.
以上の結果より、局所麻酔薬物含有含嗽剤の製剤pHを調整することにより、薬物の効果が有意に改善された。
From the above results, the drug effect was significantly improved by adjusting the formulation pH of the local anesthetic drug-containing gargle.
Claims (4)
4. The local anesthetic drug-containing gargle according to any one of claims 1 to 3, wherein the formulation pH is 6.5 or more and less than 7.5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003278888A JP2005041832A (en) | 2003-07-24 | 2003-07-24 | Gargle containing local anesthetic |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003278888A JP2005041832A (en) | 2003-07-24 | 2003-07-24 | Gargle containing local anesthetic |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2005041832A true JP2005041832A (en) | 2005-02-17 |
Family
ID=34265160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003278888A Pending JP2005041832A (en) | 2003-07-24 | 2003-07-24 | Gargle containing local anesthetic |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2005041832A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009157377A1 (en) * | 2008-06-24 | 2009-12-30 | 田中 和美 | Buccal anaesthetic |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11222427A (en) * | 1998-02-03 | 1999-08-17 | Bitakain Seiyaku Kk | Stabilization of aqueous solution of lidocaine or its salt and aqueous solution of lidocaine or its salt |
JP2002275093A (en) * | 2001-01-10 | 2002-09-25 | Showa Yakuhin Kako Kk | Local anesthetic composition |
JP2003511463A (en) * | 1999-10-12 | 2003-03-25 | サイトビア インコーポレイテッド | Caspase inhibitors for the treatment and prevention of cell death induced by chemotherapy and radiation therapy |
-
2003
- 2003-07-24 JP JP2003278888A patent/JP2005041832A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11222427A (en) * | 1998-02-03 | 1999-08-17 | Bitakain Seiyaku Kk | Stabilization of aqueous solution of lidocaine or its salt and aqueous solution of lidocaine or its salt |
JP2003511463A (en) * | 1999-10-12 | 2003-03-25 | サイトビア インコーポレイテッド | Caspase inhibitors for the treatment and prevention of cell death induced by chemotherapy and radiation therapy |
JP2002275093A (en) * | 2001-01-10 | 2002-09-25 | Showa Yakuhin Kako Kk | Local anesthetic composition |
Non-Patent Citations (2)
Title |
---|
JPN6009059968, 安野伸浩 他, "Stability and Clinical Application of Azunol Elase Xylocaine Gargle (AEXG) in Hospital Preparation.", 病院薬学, 1995, Vol.21, No.4, p.327−334 * |
JPN6009059969, 佐藤悦子 他, "Studies on the Stability of Azunol Xylocain Oradol Gargle (OAKG).", 病院薬学, 1993, Vol.19, No.3, p.196−202 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009157377A1 (en) * | 2008-06-24 | 2009-12-30 | 田中 和美 | Buccal anaesthetic |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4669960B2 (en) | Oral or pharyngeal preparations containing local anesthetics | |
ES2402618T3 (en) | Uses and means to obtain bronchial relaxation | |
WO2018201024A1 (en) | Amino acid compositions and their use for the treatment of traumatic brain injury | |
EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
JP3929618B2 (en) | Solid oral pharmaceutical composition for treatment of mouth-dissolving or chewing type rhinitis | |
EP2957282A1 (en) | Oral antiseptic composition for treating oral mucositis | |
CA3127926A1 (en) | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa | |
BRPI1005537A2 (en) | iron bisglycinate chelate | |
ES2793724T3 (en) | Pediatric formulation | |
JP2002332229A (en) | Composition for common cold | |
CN109646452A (en) | Artificial saliva | |
JP2006347958A (en) | Antiinflammatory spray for pharyngeal mucosa | |
PT866711E (en) | Montirelin for inhibiting sleep apnea | |
TW201818921A (en) | Acetaminophen and tramadol cosolvent compound analgesic oral liquid capable of solving the problem associated with using oral analgesic lozenges due to difficulties in swallowing | |
JP2005041832A (en) | Gargle containing local anesthetic | |
JP4775807B2 (en) | Local anesthetic drug-containing jelly | |
EP2566449A2 (en) | Pharmaceutical compositions comprising ceftibuten | |
JP2002308764A (en) | Pharmaceutical composition for ophthalmic use | |
WO2000074685A1 (en) | Oral preparations of etidronate disodium | |
KR102083621B1 (en) | Oral liquid formulation having improved stability comprising ambroxol and levodropropizine | |
US20060280695A1 (en) | Methods and compositions for the prevention, suppression and elimination of oral pain | |
KR20150085131A (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | |
JP5336527B2 (en) | Lidocaine-containing jelly | |
JP2004026725A (en) | Solid preparation | |
EP3678498B1 (en) | Composition for calcium supplementation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060531 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091202 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100518 |